"Haemophilus Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines containing antigenic polysaccharides from Haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine.
| Descriptor ID |
D018073
|
| MeSH Number(s) |
D20.215.894.135.450
|
| Concept/Terms |
Haemophilus Vaccines- Haemophilus Vaccines
- Vaccines, Haemophilus
- Hemophilus Vaccines
- Vaccines, Hemophilus
- Haemophilus influenzae Vaccines
- Vaccines, Haemophilus influenzae
- Haemophilus Vaccine
- Vaccine, Haemophilus
|
Below are MeSH descriptors whose meaning is more general than "Haemophilus Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Haemophilus Vaccines".
This graph shows the total number of publications written about "Haemophilus Vaccines" by people in this website by year, and whether "Haemophilus Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 4 | 0 | 4 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Haemophilus Vaccines" by people in Profiles.
-
Demographic and pathogen characteristics of incident bacterial meningitis in infants in South Africa: A cohort study. PLoS One. 2024; 19(9):e0310528.
-
Effect of cytomegalovirus infection on humoral immune responses to select vaccines administered during infancy. Vaccine. 2021 08 09; 39(34):4793-4799.
-
Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa. Hum Vaccin Immunother. 2021 06 03; 17(6):1770-1778.
-
Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Hum Vaccin Immunother. 2019; 15(3):658-668.
-
Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy. Clin Infect Dis. 2017 Nov 13; 65(11):1897-1904.
-
Effect of HIV-1 exposure and antiretroviral treatment strategies in HIV-infected children on immunogenicity of vaccines during infancy. AIDS. 2014 Feb 20; 28(4):531-41.
-
Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatr Infect Dis J. 2013 Aug; 32(8):889-97.
-
Review of a new fully liquid, hexavalent vaccine: Hexaxim. Expert Opin Biol Ther. 2013 Apr; 13(4):575-93.
-
One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18 - 19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine. S Afr Med J. 2011 Nov 28; 101(12):879-83.
-
Invasive disease due to Haemophilus influenzae serotype b ten years after routine vaccination, South Africa, 2003-2009. Vaccine. 2012 Jan 11; 30(3):565-71.